【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2016-2026
3.1 The World Ophthalmic Drugs Market in 2015
3.2 World Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2016-2026
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2016-2026
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2016-2026
3.5.3 Glaucoma Drugs Market: Sales Forecast 2016-2026
3.5.4 Dry Eye Drugs Market: Sales Forecast 2016-2026
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.6 How Will Market Shares Change to 2026?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2016-2026
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drug Manufacturers 2016-2026
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2016?
4.1.1.2 Restasis: Sales Forecast 2016-2026
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2016-2026
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2026
4.1.1.8 Acular: New Forms Receiving FDA Approvals
4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2016-2026
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2016-2026
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.2.1.2 Xalatan/Xalacom: Sales Forecast 2016-2026
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2016-2026
4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2016-2026
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.3.1.2 Eylea: US Sales Forecast 2016-2026
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2016-2026
4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2016-2026
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck
4.4.2 Akorn: Revenue Forecast 2016-2026
4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2016-2026
4.4.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers 2016-2026
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2016-2026
5.1.3 Bayer: Revenue Forecast 2016-2026
5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Still a Leading Drug in AMD
5.2.1.2 Lucentis: Non-US Sales Forecast 2016-2026
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2026
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2016-2026
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2016-2026
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2016-2026
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2016-2026
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2016-2026
5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales
5.3.1.3 Avastin: Sales Forecast 2016-2026
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2016-2026
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2016-2026
5.3.4 Roche: SWOT Analysis
6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2016-2026
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2016-2026
6.1.1.2 Hyalein
6.1.1.3 Hyalein: Sales Forecast 2016-2026
6.1.1.4 Cosopt: Non-US Sales Forecast 2016-2026
6.1.1.5 Tapros/Taflotan: Sales Forecast 2016-2026
6.1.1.6 Diquas: Sales Forecast 2016-2026
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2016-2026
6.1.1.9 Alesion: Sales Forecast 2016-2026
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2016-2026
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2016-2026
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2016-2026
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2016-2026
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Lotemax: New Formulation Launch Expected in 2016
6.3.1.2 Lotemax: Sales Forecast 2016-2026
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (Latanoprostene Bunod)
6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2016-2026
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2016-2026
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt
7. Emerging Ophthalmic Drug Manufacturers in 2016
7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2016
7.2 Acucela
7.3 Aerie Pharmaceuticals
7.4 Aerpio Therapeutics: Developing AKB 9778
7.5 Alimera Sciences
7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.6 Amakem
7.7 Ampio Pharmaceuticals
7.8 Chengdu Kanghong Pharmaceutical
7.9 Eleven Biotherapeutics
7.10 EyeGate Pharmaceuticals
7.11 Gene Signal
7.11.1 Aganirsen: Preventing Corneal Graft Rejection
7.12 Icon Bioscience
7.13 MacuCLEAR
7.13.1 MC 1101: a Potential Therapy for Dry AMD
7.14 Neurotech
7.15 Omeros
7.16 OphthaliX (Can-Fite BioPharma)
7.17 Ophthotech
7.17.1 Fovista: Potential Game-Changer in AMD
7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.17.3 Zimura: Complement C5 Inhibitor
7.18 Otsuka Pharmaceutical
7.19 pSivida Corp.
7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.21 Shire
7.21.1 Lifitegrast (SHP606) for Dry Eye
7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.22 ThromboGenics
7.22.1 Jetrea (ocriplasmin)
7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline
8. Qualitative Analysis of the Ophthalmic Drugs Market 2016-2026
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2015
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drugs Companies
9.3 World Ophthalmic Drugs Market Forecast 2016-2026
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?
10. Glossary
【レポート販売概要】
■ タイトル：医薬品有力企業シリーズ： 眼薬メーカー上位25社分析2016-2026■ 英文：Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
■ 発行日：2016年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN60620
■ 調査対象地域：グローバル
- LTE及びLTE BeyondにおけるキャリアWiFi及びスモールセル市場機会と予測Mobile network operator “Heterogeneous Networks” (HetNet) are based on a combination of small cells, macro cells and carrier WiFi. HetNets are expected to play a pivotal role in addressing network capacity needs, bring about improvements in carrier operations, and create opportunities for new revenue streams. This research provides an in-depth assessment of the carrier WiFi and small cells market, …
- テトロドトキシンの世界市場Tetrodotoxin (CAS 4368-28-9) Market Research Report 2013 presents comprehensive data on Tetrodotoxin markets globally and regionally (Europe, Asia, North America etc.) The Tetrodotoxin (CAS 4368-28-9) Market Research Report 2013 includes Tetrodotoxin description, covers its application areas and related patterns. It overviews Tetrodotoxin market, names Tetrodotoxin producers and indicates its supp …
- 産業用コントロールバルブの世界市場：スライディングステム調節弁、回転シャフト調節弁About Industrial Control Valves Industrial control valves are devices that are used to regulate the flow of fluids and gases. They are also used to regulate pressure within the system. Control valves monitor flow, temperature, and pressure by utilizing signals and partially or fully open or close as per the requirement. Sensors provide changes in conditions which are then compared to a set point. …
- 整流器用変圧器の世界市場This report estimates the global converter transformer market in terms of value in USD million. This has been broken down into regions, and further split into countries. Increased focus on renewable energy generation has been a key trend in the global power industry scenario. Countries are progressively investing into renewable power projects to ensure sustainable increase in their unconventional …
- ゼラチンの世界市場2017-2021About Gelatin Gelatin is a colorless, flavorless, semi-transparent, and brittle collagen product. It is a protein food product generally derived from the several animal sources. It is used in several applications as a stabilizer, thickener, and gelling agent. Gelatin is normally graded into categories as per its quality and strength, and the unit is named as 'bloom.' A greater bloom number signifi …
- CRMアウトソーシングの世界市場2018-2022About CRM Outsourcing Customer relationship management (CRM) outsourcing is a type of professional service provided by outsourcing vendors in the form of third-party services. The services include communications management, multi-channel customer engagement, and analytic solutions. Technavio’s analysts forecast the global CRM outsourcing market to grow at a CAGR of 5.94% during the period 2018-202 …
- 世界の艦艇及び水上戦闘艦艇市場動向2013-2023Why was the report written? “The Global Naval Vessels and Surface Combatants Market 2013-2023” offers the reader detailed analysis of the global Naval Vessels and Surface Combatants market over the next ten years, alongside potential market opportunities to enter the industry, using detailed market size forecasts. What are the key drivers behind recent market changes? The global naval vessels and …
- 帯電防止剤の世界市場2015-2019About antistatic agents Antistatic agents are additives that are added to polymers to reduce the build-up of static charge in various materials. Build-up of static charges on the surface of materials affects their functioning. Antistatic agents attract moisture to the surface of the materials. While the amount of moisture from the surroundings may not be enough to wet the surface, it is sufficient …
- 世界の液晶ポリマー(LCP)市場2015The Global Liquid Crystalline Polymers (LCP) Industry Report 2015 is a professional and in-depth study on the current state of the Liquid Crystalline Polymers (LCP) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Liquid Crystalline Polymers (LCP) market analysis is provided for the international ma …
- 人工内耳の世界市場分析：装着方法別（片耳用、両耳用）、エンドユーザー別（大人、小児）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA）、セグメント予測、2014-2025The global cochlear implants market is expected to reach a value of USD 3.1 billion by 2025, based on a new report by Grand View Research, Inc. The cochlear implants market is anticipated to witness significant growth during the forecast period, which can be attributed to a favorable reimbursement scenario, rising awareness about hearing aids, and increasing adoption of implants. Furthermore, tech …
- 世界のヘリコバクター・ピロリ検査市場The report presents a detailed analysis of the Helicobacter Pylori diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the H. Pylori definition, epidemiology and etiology of are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- ICT投資の優先順位：保険産業部門 – 企業のICT投資計画Why was the report written? In order to provide deeper insights into insurers’ ICT investment priorities and strategic objectives. What is the current market landscape and what is changing? The insurance industry has been rather slow to adopt cloud computing, due to strict regulations and security issues. What are the key drivers behind recent market changes? Kable believes that demand for cloud c …
- 世界のゼロ・カロリー甘味料市場動向（2014～2018）TechNavio's analysts forecast the Global Zero-calorie Sweetener market to grow at a CAGR of 4.69 percent over the period 2013-2018. One of the key factors contributing to this market growth is the growing health-consciousness across the world. The Global Zero-calorie Sweetener market has also been witnessing the rise in consumer income levels in emerging countries. However, the negative criticisms …
- 世界の固定通信産業：Global Fixed Line Telecommunication IndustryA fixed line phone refers to a telephone line which travels through a solid medium, either metal wire or optical fiber, as distinguished from a mobile cellular line, where transmission is via radio waves. Fixed lines usually have a lower price for calling time, and the user hardware costs less than mobile phones, but they are less convenient. Aruvian’s R’search presents an analysis of the global f …
- 断路器の世界市場2015-2019About disconnect switches Disconnect switches help isolate electrical circuits for inspection and maintenance schedules. They include low, medium, and high-voltage switches. Low-voltage disconnect switches can be mounted on switchboards, panel boards, or wall mounts. Vendors also offer fused or non-fused disconnects, and electrically closed and electrically opened devices. Low-voltage disconnect s …
